Timeline
Crism Therapeutics
Crism Therapeutics clears site setup for glioblastoma trial
Crism Therapeutics shares rose after FDA Orphan Drug Designation
CRISM Therapeutics lands UK grant for Phase 2 glioblastoma trial
CRISM Therapeutics lands Northern Ireland grant for ChemoSeed prostate programme
CRISM Therapeutics launches retail offer to raise up to £100,000
CRISM Therapeutics raises £2.5m to fund Phase 2 trial and grant pursuit
CRISM Therapeutics shows 58% tumour reduction with Docetaxel-ChemoSeed
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.